Rhythm Appoints Board Members
This article was originally published in Scrip
Executive Summary
Rhythm has appointed David Meeker, president and CEO of Sanofi's subsidiary Genzyme, and David McGirr, former chief financial officer of Cubist Pharmaceuticals, to its board of directors. Before joining Genzyme in 1994, Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and assistant professor of medicine at Ohio State University. Previously, McGirr was senior advisor to the CEO of Cubist and from 2002 to 2013; he was senior vice president and CFO of the company. Prior to Cubist, McGirr was president and chief operating officer of internet technology company Hippo Inc., and he previously served as president and CEO of GAB Robins North America, Inc.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.